Novus Therapeutics Stock Price, News & Analysis (NASDAQ:NVUS)

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

Novus Therapeutics Inc (NASDAQ:NVUS) issued its quarterly earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.35). View Novus Therapeutics' Earnings History.

Novus Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Novus Therapeutics.

1 analysts have issued 1-year price targets for Novus Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Novus Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,751.5% from the stock's current price. View Analyst Price Targets for Novus Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novus Therapeutics.

Press coverage about NVUS stock has trended negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Novus Therapeutics earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Novus Therapeutics.

Novus Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 28,800 shares, an increase of 35.8% from the August 30th total of 21,200 shares. Based on an average daily volume of 67,600 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the company are sold short. View Novus Therapeutics' Current Options Chain.

Some companies that are related to Novus Therapeutics include Bio-Path (BPTH), Zafgen (ZFGN), China SXT Pharmaceuticals (SXTC), Aptevo Therapeutics (APVO), Aerpio Pharmaceuticals (ARPO), Provectus Biopharmaceuticals (PVCT), Sierra Oncology (SRRA), ContraFect (CFRX), Intec Pharma (NTEC), Acerus Pharmaceuticals (ASPCF), OncoSec Medical (ONCS), Acerus Pharmaceuticals (TRLPF), Ceapro (CRPOF), Mateon Therapeutics (MATN) and ProPhase Labs (PRPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT) and Verastem (VSTM).

Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVUS stock can currently be purchased for approximately $0.54.

Novus Therapeutics has a market capitalization of $7.01 million. The biopharmaceutical company earns $-14,060,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. View Additional Information About Novus Therapeutics.

The official website for Novus Therapeutics is http://novustherapeutics.com/.

Novus Therapeutics' mailing address is 19900 MACARTHUR BLVD. SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected]